i-Tail bets on treats, private label, and global expansion
Bottom line
Version 1 — Brief
i-Tail is leaning harder into pet treats, private-label manufacturing, and global expansion, according to an interview with company leaders published by GlobalPETS. The strategy lines up with the Thai manufacturer’s latest financial results: i-Tail reported THB 18.223 billion in FY2025 sales, up 2.8% year over year, while pet treats rose 36.5% to THB 2.801 billion. The company’s filings also show stronger momentum in the Americas, where FY2025 sales increased 17.8%, supported by private-label expansion and new product launches. As part of Thai Union, i-Tail is also tying that growth story to SeaChange 2030, its parent company’s sustainability framework. (market.sec.or.th)
Why it matters: For veterinary professionals, the takeaway isn’t just that treats are growing faster than core food categories. It’s that manufacturers are putting more R&D, marketing, and production capacity behind functional treats, premium formats, and retailer or partner-branded products. i-Tail’s own 2026 innovation update says the market is shifting toward foods and treats with clearer health benefits, while first-quarter FY2026 results showed treats reaching 20.8% of sales and growing 95% year over year. That could mean more treat-led wellness claims, more private-label options reaching clinics and retail channels, and more questions from pet parents about how treats fit into complete-and-balanced nutrition plans. (i-tail.com)
What to watch: Watch whether i-Tail can sustain treat-led growth in 2026, especially in the Americas, while scaling private-label business and meeting its sustainability targets for sourcing, packaging, and manufacturing. (market.sec.or.th)
Version 2 — Full analysis
i-Tail is signaling that its next phase of growth will come from pet treats, private-label manufacturing, and broader global reach. In an interview with GlobalPETS, executives described a strategy centered on scaling the higher-growth parts of the portfolio, a direction that matches the company’s FY2025 results and more recent disclosures. i-Tail ended FY2025 with THB 18.223 billion in total sales, up 2.8% year over year, with treats standing out as the fastest-growing category. (market.sec.or.th)
That emphasis didn’t emerge in a vacuum. i-Tail, part of Thai Union, has long operated as a premium wet food and treats manufacturer with a strong private-label and OEM base. Thai Union describes i-Tail as a global premium pet food manufacturer serving leading brands and pet parents worldwide, with capabilities spanning wet food, treats, and custom private-label development. In parallel, the broader market has been moving in i-Tail’s favor: industry reporting has pointed to continued growth in private-label pet care, particularly as retailers and consumers look for value without fully stepping away from premium positioning. (thaiunion.com)
The financial details help explain why treats are now getting so much attention. In i-Tail’s FY2025 management discussion and analysis, pet treats rose 36.5% year over year to THB 2.801 billion, compared with 7.9% growth in dog food and a 4.1% decline in cat food. In the fourth quarter alone, treats climbed 43.3% year over year to THB 872 million. Regionally, the Americas were the main growth engine, with FY2025 sales up 17.8% to THB 10.529 billion, which the company attributed to private-label expansion and new product launches. Europe improved later in the year, while Asia and Oceania declined 16.7%, reflecting weaker demand from a major client and softer conditions in Japan. (market.sec.or.th)
Channel mix adds another layer. For FY2025, nearly half of i-Tail’s pet food sales came from what it calls “world pet food companies,” while private label represented 16.0% of mix, essentially flat year over year. That may sound modest, but more recent results suggest the private-label piece is gaining speed: i-Tail’s first-quarter FY2026 update said private-label mix increased by 7 percentage points year over year, while treats accounted for 20.8% of sales and grew 95% year over year. Separately, the company’s 2026 innovation announcement said it wants innovation to contribute 15% of revenue this year, with leadership pointing to demand for foods and treats with clear health benefits. (market.sec.or.th)
On sustainability, i-Tail is framing expansion alongside Thai Union’s SeaChange 2030 agenda. On its sustainability page, the company says it is working toward zero water discharge, zero waste to landfill, and zero food loss in production, and supports a target for sustainable packaging in at least 60% of private-label products. It also says it aligns with Thai Union commitments on responsible seafood, certified soy oil, and responsibly sourced chicken. That matters because large retail and brand partners increasingly want proof points on sourcing, packaging, and manufacturing, especially as private-label programs scale internationally. (i-tail.com)
Why it matters: For veterinary professionals, this is a business story with clinical implications. Treats are no longer just an add-on category; they’re becoming a major innovation platform for palatability, supplementation, bonding, training, and condition-specific positioning. As manufacturers push further into functional and premium treats, clinics may see more pet parents asking whether these products support dental health, mobility, skin and coat health, weight management, or gastrointestinal wellness, and whether those claims are meaningful. The rise of private-label and partner-branded formats could also widen the range of products entering hospitals, specialty retail, and e-commerce, making nutritional guidance and label literacy more important in everyday practice. (i-tail.com)
There’s also a supply-side angle worth watching. A manufacturer that combines global scale, private-label capability, and sustainability commitments can become an important behind-the-scenes player in what pet parents and clinics actually see on shelves. If i-Tail continues to win business in the Americas and Europe, veterinary teams may encounter a growing number of different labels that share similar manufacturing origins, ingredient strategies, or treat formats. That doesn’t automatically change clinical value, but it can affect consistency, availability, pricing, and how products are positioned to pet parents. (market.sec.or.th)
What to watch: The next signals will likely come from 2026 quarterly results, especially whether treat growth stays elevated, whether private-label mix continues rising, and how i-Tail balances expansion with SeaChange 2030 goals on sourcing, packaging, and manufacturing performance. (market.sec.or.th)